|
Gene: SLC2A2 |
Gene summary for SLC2A2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC2A2 | Gene ID | 6514 |
Gene name | solute carrier family 2 member 2 | |
Gene Alias | GLUT2 | |
Cytomap | 3q26.2 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P11168 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6514 | SLC2A2 | NAFLD1 | Human | Liver | NAFLD | 1.37e-08 | 9.18e-01 | -0.04 |
6514 | SLC2A2 | S43 | Human | Liver | Cirrhotic | 2.77e-13 | 1.93e-02 | -0.0187 |
6514 | SLC2A2 | S44 | Human | Liver | HCC | 8.45e-04 | 6.21e-01 | -0.0083 |
6514 | SLC2A2 | HCC1_Meng | Human | Liver | HCC | 4.22e-23 | -3.62e-01 | 0.0246 |
6514 | SLC2A2 | HCC2_Meng | Human | Liver | HCC | 3.52e-14 | -4.35e-01 | 0.0107 |
6514 | SLC2A2 | cirrhotic1 | Human | Liver | Cirrhotic | 7.40e-07 | 6.11e-02 | 0.0202 |
6514 | SLC2A2 | cirrhotic2 | Human | Liver | Cirrhotic | 1.80e-06 | 3.48e-02 | 0.0201 |
6514 | SLC2A2 | cirrhotic3 | Human | Liver | Cirrhotic | 7.71e-03 | -2.69e-01 | 0.0215 |
6514 | SLC2A2 | HCC1 | Human | Liver | HCC | 5.04e-44 | 7.60e+00 | 0.5336 |
6514 | SLC2A2 | HCC2 | Human | Liver | HCC | 4.56e-29 | 4.94e+00 | 0.5341 |
6514 | SLC2A2 | Pt13.a | Human | Liver | HCC | 4.64e-03 | -2.59e-01 | 0.021 |
6514 | SLC2A2 | Pt13.b | Human | Liver | HCC | 1.48e-06 | -2.91e-01 | 0.0251 |
6514 | SLC2A2 | S015 | Human | Liver | HCC | 2.36e-05 | 6.10e-02 | 0.2375 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0015749 | Liver | NAFLD | monosaccharide transmembrane transport | 21/1882 | 116/18723 | 5.54e-03 | 4.23e-02 | 21 |
GO:1904659 | Liver | NAFLD | glucose transmembrane transport | 20/1882 | 110/18723 | 6.36e-03 | 4.69e-02 | 20 |
GO:0034219 | Liver | NAFLD | carbohydrate transmembrane transport | 21/1882 | 118/18723 | 6.77e-03 | 4.79e-02 | 21 |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049316 | Liver | NAFLD | Insulin resistance | 29/1043 | 108/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 29 |
hsa0493111 | Liver | NAFLD | Insulin resistance | 29/1043 | 108/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 29 |
hsa052308 | Liver | Cirrhotic | Central carbon metabolism in cancer | 30/2530 | 70/8465 | 1.41e-02 | 4.35e-02 | 2.68e-02 | 30 |
hsa0492221 | Liver | Cirrhotic | Glucagon signaling pathway | 43/2530 | 107/8465 | 1.42e-02 | 4.35e-02 | 2.68e-02 | 43 |
hsa0523011 | Liver | Cirrhotic | Central carbon metabolism in cancer | 30/2530 | 70/8465 | 1.41e-02 | 4.35e-02 | 2.68e-02 | 30 |
hsa0492231 | Liver | Cirrhotic | Glucagon signaling pathway | 43/2530 | 107/8465 | 1.42e-02 | 4.35e-02 | 2.68e-02 | 43 |
hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0492241 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa0523021 | Liver | HCC | Central carbon metabolism in cancer | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0492251 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa0523031 | Liver | HCC | Central carbon metabolism in cancer | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC2A2 | SNV | Missense_Mutation | novel | c.1285N>G | p.Gln429Glu | p.Q429E | P11168 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
SLC2A2 | SNV | Missense_Mutation | c.1280N>C | p.Phe427Ser | p.F427S | P11168 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-34-5929-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC2A2 | SNV | Missense_Mutation | novel | c.767C>G | p.Ala256Gly | p.A256G | P11168 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-37-3792-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC2A2 | SNV | Missense_Mutation | novel | c.263N>A | p.Ala88Glu | p.A88E | P11168 | protein_coding | tolerated(0.98) | benign(0.005) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC2A2 | SNV | Missense_Mutation | rs751917665 | c.995N>T | p.Thr332Met | p.T332M | P11168 | protein_coding | tolerated(0.11) | benign(0.075) | TCGA-39-5027-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SLC2A2 | SNV | Missense_Mutation | novel | c.441N>T | p.Leu147Phe | p.L147F | P11168 | protein_coding | tolerated(0.23) | benign(0.021) | TCGA-39-5034-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC2A2 | SNV | Missense_Mutation | novel | c.877N>A | p.Gln293Lys | p.Q293K | P11168 | protein_coding | tolerated(0.07) | benign(0.022) | TCGA-56-8629-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC2A2 | SNV | Missense_Mutation | c.736C>G | p.Leu246Val | p.L246V | P11168 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-77-8133-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC2A2 | SNV | Missense_Mutation | c.400N>G | p.Leu134Val | p.L134V | P11168 | protein_coding | deleterious(0.03) | benign(0.284) | TCGA-85-7843-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC2A2 | SNV | Missense_Mutation | novel | c.1193N>T | p.Tyr398Phe | p.Y398F | P11168 | protein_coding | tolerated(0.12) | possibly_damaging(0.599) | TCGA-CQ-5332-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6514 | SLC2A2 | TRANSPORTER, DRUGGABLE GENOME | 178101360 | |||
6514 | SLC2A2 | TRANSPORTER, DRUGGABLE GENOME | GLUFOSFAMIDE | GLUFOSFAMIDE | ||
6514 | SLC2A2 | TRANSPORTER, DRUGGABLE GENOME | metformin | METFORMIN |
Page: 1 |